Position in ABBV
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$3,449,481
+$495,532 QoQ
Shares Held
13,708
+0.9% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#1,553
of 4,153 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 72%
Shared 0%
None 28%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SCS Capital Management LLC holds $66,090,703 across 9 Drug Manufacturers - General names. ABBV ranks #4 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
105,264 | $26,733,898 | |
| 2 | AZN |
Astrazeneca PLC
|
84,223 | $15,970,365 | |
| 3 | LLY |
ELI LILLY & Co
|
11,357 | $13,621,927 | |
| 4 | ABBV |
AbbVie Inc.
This page
|
13,708 | $3,449,481 | |
| 5 | MRK |
Merck & Co., Inc.
|
21,998 | $2,826,743 | |
| 6 | AMGN |
Amgen Inc
|
4,468 | $1,617,952 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
6,609 | $834,981 | |
| 8 | PFE |
Pfizer Inc
|
27,645 | $665,691 |
All Filings in ABBV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,449,481 | 13,708 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $2,953,949 | 13,582 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $3,439,916 | 15,055 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $3,468,469 | 14,980 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $4,562,168 | 24,578 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $3,687,552 | 17,600 | Shares | Sole | 2025-05-19 | |
| No filing history on record for this holder in this stock. | ||||||